Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Malignant Lymphoma

  Free Subscription


Articles published in Eur J Haematol

Retrieve available abstracts of 34 articles:
HTML format
Text format



Single Articles


    January 2018
  1. TANAKA Y, Maeshima AM, Nomoto J, Makita S, et al
    Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
    Eur J Haematol. 2018 Jan 28. doi: 10.1111/ejh.13033.
    PubMed     Text format     Abstract available


    November 2017
  2. LI JW, Li YJ, Zhong MZ, Liu XL, et al
    Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-Cell lymphoma: A multicenter retrospective study.
    Eur J Haematol. 2017 Nov 30. doi: 10.1111/ejh.13004.
    PubMed     Text format     Abstract available


  3. SCHILLER J, Klein S, Engels M, Buttner R, et al
    A Cryptosporidium infection in a patient with relapsed T lymphoblastic lymphoma undergoing allogeneic stem cell transplantation.
    Eur J Haematol. 2017 Nov 15. doi: 10.1111/ejh.12998.
    PubMed     Text format     Abstract available


    October 2017
  4. HOLLANDER P, Rostgaard K, Smedby KE, Molin D, et al
    An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome.
    Eur J Haematol. 2017 Oct 24. doi: 10.1111/ejh.12987.
    PubMed     Text format     Abstract available


  5. ELORANTA S, Branvall E, Celsing F, Papworth K, et al
    Increasing incidence of Primary CNS lymphoma but no improvement in survival in Sweden 2000-2013.
    Eur J Haematol. 2017 Oct 6. doi: 10.1111/ejh.12980.
    PubMed     Text format     Abstract available


    September 2017
  6. BROCKELMANN PJ, Zagadailov EA, Corman SL, Chirikov V, et al
    Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma who are Ineligible for Autologous Stem Cell Transplant: A Germany and UK Retrospective Study.
    Eur J Haematol. 2017 Sep 26. doi: 10.1111/ejh.12973.
    PubMed     Text format     Abstract available


    May 2017
  7. GLAVEY S, Quinn J, McCloy M, Sargent J, et al
    Emergence of Bruton's Tyrosine Kinase-negative Hodgkin Lymphoma During Ibrutinib Treatment of Chronic Lymphocytic Leukaemia.
    Eur J Haematol. 2017 May 31. doi: 10.1111/ejh.12911.
    PubMed     Text format     Abstract available


  8. KAWAMOTO K, Miyoshi H, Yanagida E, Yoshida N, et al
    Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
    Eur J Haematol. 2017;98:459-466.
    PubMed     Text format     Abstract available


    February 2017
  9. DAVIES JM, Osborne TR, Edmonds PM, Schey SA, et al
    The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma.
    Eur J Haematol. 2017 Feb 3. doi: 10.1111/ejh.12864.
    PubMed     Text format     Abstract available


  10. SEKINE M, Kubuki Y, Kameda T, Takeuchi M, et al
    Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
    Eur J Haematol. 2017 Feb 2. doi: 10.1111/ejh.12863.
    PubMed     Text format     Abstract available


  11. THOTA S, Advani A
    Inotuzumab ozogamicin in relapsed b-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2017 Feb 2. doi: 10.1111/ejh.12862.
    PubMed     Text format     Abstract available


    December 2016
  12. THAKRAL B, Medeiros LJ, Desai P, Lin P, et al
    Prognostic Impact of CD5 Expression in Diffuse Large B-cell Lymphoma in Patients Treated with Rituximab-EPOCH.
    Eur J Haematol. 2016 Dec 31. doi: 10.1111/ejh.12847.
    PubMed     Text format     Abstract available


  13. ADAMS HJ, Kwee TC
    Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis.
    Eur J Haematol. 2016 Dec 10. doi: 10.1111/ejh.12837.
    PubMed     Text format     Abstract available


    November 2016
  14. BENDTSEN MD, Munksgaard PS, Severinsen MT, Bekric E, et al
    Anthropometrics and Prognosis in Diffuse Large B-Cell Lymphoma: A Multicentre Study of 653 Patients.
    Eur J Haematol. 2016 Nov 28. doi: 10.1111/ejh.12835.
    PubMed     Text format     Abstract available


  15. HERTING F, Herter S, Friess T, Muth G, et al
    Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
    Eur J Haematol. 2016;97:461-470.
    PubMed     Text format     Abstract available


    October 2016
  16. LASICA M, Taylor E, Bhattacharyya P, Bennett A, et al
    Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning.
    Eur J Haematol. 2016;97:348-52.
    PubMed     Text format     Abstract available


    August 2016
  17. ADAMS HJ, Kwee TC
    Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
    Eur J Haematol. 2016 Aug 16. doi: 10.1111/ejh.12791.
    PubMed     Text format     Abstract available


  18. KNITTEL G, Liedgens P, Korovkina D, Pallasch CP, et al
    Rewired NFkappaB signaling as a potentially actionable feature of activated B cell-like diffuse large B cell lymphoma.
    Eur J Haematol. 2016 Aug 16. doi: 10.1111/ejh.12792.
    PubMed     Text format     Abstract available


    June 2016
  19. DELFOROUSH M, Berglund M, Edqvist PH, Sundstrom C, et al
    Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.
    Eur J Haematol. 2016 Jun 14. doi: 10.1111/ejh.12784.
    PubMed     Text format     Abstract available


    May 2016
  20. MIGUEL AC, Paola L, Ernesto CL, Maria GJ, et al
    Long term complication in follicular lymphoma: assessing the risk of second neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab tiuxetan.
    Eur J Haematol. 2016 May 9. doi: 10.1111/ejh.12775.
    PubMed     Text format     Abstract available


  21. MALY J, Alinari L
    Pembrolizumab in Classical Hodgkin's Lymphoma.
    Eur J Haematol. 2016 May 5. doi: 10.1111/ejh.12770.
    PubMed     Text format     Abstract available


  22. LEMMA SA, Pasanen AK, Haapasaari KM, Sippola A, et al
    Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
    Eur J Haematol. 2016;96:492-501.
    PubMed     Text format     Abstract available


    April 2016
  23. ZINZANI PL, Corradini P, Martelli M, Minotti G, et al
    Critical concepts, practice recommendations and research perspectives of pixantrone therapy in non-Hodgkin lymphoma. A SIE, SIES, GITMO consensus paper.
    Eur J Haematol. 2016 Apr 28. doi: 10.1111/ejh.12768.
    PubMed     Text format     Abstract available


  24. ZAHID MF, Khan N, Hashmi SK, Kizilbash SH, et al
    Central nervous system prophylaxis in diffuse large B-cell lymphoma.
    Eur J Haematol. 2016 Apr 20. doi: 10.1111/ejh.12763.
    PubMed     Text format     Abstract available


  25. ZHU Y, Tan Y, Ou R, Zhong Q, et al
    Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
    Eur J Haematol. 2016;96:389-96.
    PubMed     Text format     Abstract available


    March 2016
  26. GORDON MJ, Danilova O, Spurgeon S, Danilov A, et al
    Cardiac non-Hodgkin lymphoma: clinical characteristics and trends in survival.
    Eur J Haematol. 2016 Mar 3. doi: 10.1111/ejh.12751.
    PubMed     Text format     Abstract available


    February 2016
  27. ENGLUND A, Molin D, Enblad G, Karlen J, et al
    The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children.
    Eur J Haematol. 2016 Feb 13. doi: 10.1111/ejh.12747.
    PubMed     Text format     Abstract available


  28. SZEKELY E, Linden O, Peterson S, Jerkeman M, et al
    Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.
    Eur J Haematol. 2016 Feb 13. doi: 10.1111/ejh.12746.
    PubMed     Text format     Abstract available


  29. GRONECK L, Quaas A, Hallek M, Zander T, et al
    Ultrasound guided core needle biopsies for work-up of lymphadenopathy and lymphoma.
    Eur J Haematol. 2016 Feb 2. doi: 10.1111/ejh.12742.
    PubMed     Text format     Abstract available


  30. PINANA JL, Sanz J, Esquirol A, Martino R, et al
    Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
    Eur J Haematol. 2016;96:128-35.
    PubMed     Text format     Abstract available


    December 2015
  31. CENCINI E, Fabbri A, Guerrini S, Mazzei MA, et al
    Long term remission in a case of Plasmablastic lymphoma treated with COMP (Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone) and Bortezomib.
    Eur J Haematol. 2015 Dec 30. doi: 10.1111/ejh.12732.
    PubMed     Text format     Abstract available


  32. BASSAN R, Maino E, Cortelazzo S
    Lymphoblastic lymphoma: an updated review on biology, diagnosis and treatment.
    Eur J Haematol. 2015 Dec 17. doi: 10.1111/ejh.12722.
    PubMed     Text format     Abstract available


    November 2015
  33. MONTES-MORENO S
    Targeting CD30 expression in diverse Large B cell lymphoma entities.
    Eur J Haematol. 2015 Nov 18. doi: 10.1111/ejh.12704.
    PubMed     Text format     Abstract available


    June 2015
  34. ALIG SK, Dreyling M, Seppi B, Aulinger B, et al
    Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
    Eur J Haematol. 2015;94:554-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: